Optimal Strategy for CMV Prevention in HCT

CE / CME

Reducing the Burden of Cytomegalovirus in HCT: Optimal Strategy for Prevention

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: July 21, 2023

Expiration: July 20, 2024

Roy F. Chemaly
Roy F. Chemaly, MD, MPH

Activity

Progress
1
Course Completed

Which of these transplant factors is associated with increased risk of early cytomegalovirus (CMV) reactivation after hematopoietic cell transplant (allo-HCT)?

Steven is undergoing allo-HCT from a mismatched donor for acute myeloid leukemia. He is 65 years old and CMV seropositive prior to the procedure. Which of these strategies to reduce CMV risk is preferred for Steven based on current American Society for Transplantation and Cellular Therapy (ASTCT) guidelines?

In a clinical trial of extended (200 days) CMV prophylaxis with letermovir vs placebo post-transplant, what percentage of allo-HCT patients developed clinically significant CMV infection with letermovir vs placebo from Week 14 to Week 28?